Tags : KEYNOTE-062

Merck Reports Updated Results of Keytruda (pembrolizumab) in P-III KEYNOTE-062

Shots: The P-III KEYNOTE-062 (NCT02494583) study involves assessing of Keytruda as monothx. and in combination with CT (cisplatin/5-fluorouracil/capecitabine) & CT as monthx. in 763 patients for the 1L treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma The P-III KEYNOTE-062 results: as monothx. met its 1EPs, noninferior to CT; as a combination therapy, no superiority […]Read More